02/12/2026
A note from CEO, Jacob Glanville:
Thirteen years in the making, I am immensely pleased and grateful to announce that our first universal vaccine, Centi-Flu 01, has entered human clinical trials. With this, Centivax becomes a clinical stage company, and the vision of a post-pandemic world and post-pathogen humanity one step closer to being realized.
My congratulations and gratitude to the Centivax team, our investors and supporters that have made this step forward to universal immunity possible. Jerry Sadoff Sawsan Youssef Stephanie Wisner Nicholas Bayless Gusti Zeiner Atsuko Sakurai-Sangria Shawna Cote Sangil Kim and the rest of the team: congratulations on this accomplishment. Steve Jurvetson Omri Amirav-Drory Anastasia Budinskaya Helen McBride, Ph.D. Vidya Vasu-Devan Victor Olmos, PhD Elliot Hershberg David Beyer Amol Jain - thank you to Future Ventures, NFX, GHIC, Base4, BOLD Capital, Amplify Bio, Kendall Capital Partners and others for making this possible and being our strategic and thought partners along the way. The vibes were immaculate.
Thank you Gates Foundation CEPI (Coalition for Epidemic Preparedness Innovations) NIH, WRAIR, NMRC, MTEC and others for your support to advance the platform and the programs. Bill Gates - the Grand Challenge award and the GLIPH awards early on were critical for success here - thank you.
There are too many others to thank here and I’ve probably linked enough people for the algorithm anyway.
Read out later this year: stay tuned.
/PRNewswire/ -- Centivax, Inc., a clinical-stage biotechnology company engineering vaccines and therapies for durable, universal protection against highly...
